-
Safety review initiated following post-surgical fatalities in ultra-rapid metabolisers
-
A letter was sent to advise healthcare professionals about a restriction to the indication and route of administration for Mitomycin-C Kyowa 40 mg following the observation of increased sub-visible particles in the drug prod…
-
Safety studies of Spiriva Respimat▼
-
Recent information relating to COVID-19 vaccines and medicines that has been published since the October 2022 issue of Drug Safety Update, up to 24 November 2022.
-
An alert was recently issued about Oxoid ceftazidime antimicrobial susceptibility test discs.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices and details of two recent MHRA National Patient Safety Alerts to remove from service Philips Health Systems V…
-
Care needed when transferring from unlicensed formulations.
-
Warnings about the risk of severe and fatal burns are being extended to all paraffin-based emollients regardless of paraffin concentration. Data suggest there is also a risk for paraffin-free emollients. Advise patients who …
-
A group of independent experts will review all evidence provided; we will publish a report of the group’s findings.
-
A summary of letters sent to relevant healthcare professionals in January 2017.
-
A summary of letters sent to relevant healthcare professionals.
-
We have recently advised that talc preparations for pleurodesis are to be considered as medicinal products.
-
An alert was issued about T34 ambulatory syringe pumps.
-
Healthcare professionals should be aware of epidemiological data showing a small increased risk of fractures associated with the use of TCAs and SSRIs, and should take this risk into account in their discussions with patient…
-
A summary of letters sent to relevant healthcare professionals in December 2016.
-
In May 2016, letters were sent regarding Nexplanon (etonogestrel implant) and ERWINASE.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines.
-
The European Medicines Agency has advised that no change in recommendations for use is required at present.
-
Recent information relating to COVID-19 vaccines and medicines that has been published since the November 2021 issue of Drug Safety Update, up to 3 December 2021.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines.
-
Check pumps after MRI.
-
Letters were sent about cladribine (Litak and Leustat), radium-223-dichloride (Xofigo▼), and ERWINASE.
-
There is a risk of harmful drug interactions with the ritonavir component of the COVID-19 treatment Paxlovid▼ due to its inhibition of the enzyme CYP3A, which metabolises many commonly used drugs. Prescribers should obtain a…
-
An alert was issued about Dialog+ haemodialysis machines.
-
Physicians should remain vigilant for pneumonia and other infections of the lower respiratory tract (ie, bronchitis) in patients with chronic obstructive pulmonary disease who are treated with inhaled products that contain s…
-
An alert was recently issued about Prismaflex haemofiltration machines.
-
Recent epidemiological evidence suggests a possible small increased risk of congenital cardiac defects in association with fluoxetine in early pregnancy, similar to that seen with paroxetine. There are insufficient data to d…
-
To be used only in patients with acute blood loss and when crystalloids alone are not sufficient.
-
The European Medicines Agency (EMA) has concluded that oral fluoroquinolone norfloxacin (Utinor) shouldn't be used to treat acute or chronic, complicated pyelonephritis.
-
Increased risk of stroke in older women should be taken into account in prescribing decisions.
-
Alerts were recently issued by MHRA about all Philips HeartStart MRx monitors/defibrillators and Boston Scientific pacemakers and CRT-P.
-
Reminder that paediatric paracetamol liquids had been developed to ensure children receive optimum dosing for their age.
-
An alert was recently issued by MHRA on JM103 and JM105 Jaundice Meters. We also remind you of an alert about Accu-Chek blood glucose test strips.
-
Cases of severe hypersensitivity syndromes, sometimes fatal, have been reported with etravirine.
-
A review of the latest evidence on the risk of thromboembolism advises to consider risk factors and remain vigilant for signs and symptoms.
- the risk of blood clots with all low-dose CHCs is small
- there is good evid…
-
Advise patients and their caregivers to seek urgent medical attention if any signs or symptoms of communicating hydrocephalus develop during nusinersen therapy for spinal muscular atrophy. Patients with communicating hydroce…
-
A summary of recent letters and notifications sent to healthcare professionals about medicines, and a recent National Patient Safety Alert highlighting the risk of deaths and serious injuries from entrapment or falls relatin…
-
Now only authorised for use in patients with symptomatic bone metastases and no known visceral metastases who have had 2 previous systemic treatments for metastatic castration-resistant prostate cancer or who cannot receive …
-
Maintenance doses of brolucizumab (after the first 3 doses) should not be given at intervals of less than 8 weeks apart.
-
There have been rare reports of Nexplanon implants having reached the lung via the pulmonary artery. An implant that cannot be palpated at its insertion site in the arm should be located as soon as possible and removed at th…
-
Don't apply aqueous calamine cream onto the skin before an X-ray examination because it may affect the outcome of the radiograph.
-
Repeat enhanced cardiovascular monitoring when restarting fingolimod after treatment interruption,
-
Cataract surgeons should check past or current use of α-1 adrenoreceptor antagonists for prostatic hypertrophy before surgery.
-
Alerts were recently issued about high concentration oxygen masks, metal-on-metal (MoM) hip replacements, and BVM (Bag-Valve-Mask) manual resuscitation systems.
-
Serious liver injury has been reported during treatment with pirfenidone in the first year after initiation, including 2 cases with a fatal outcome. Measure alanine aminotransferase (ALT), aspartate aminotransferase (AST), a…
-
Taking zolpidem is associated with a risk of impaired driving ability the next day.
-
Contraindicated in patients with any known current cancer
-
A case of progressive multifocal leukoencephalopathy (PML) with a fatal outcome was reported in a patient with rheumatoid arthritis who had not previously received treatment with methotrexate or a TNF antagonist.
-
Healthcare professionals should not prescribe them to newly diagnosed patients as first-line treatment, except for those with severe hypertriglyceridaemia or those who cannot take statins.
-
Risk of intraocular lens opacification.